In June 2022 we reported that favourable results from a trial of a new cancer drug, Enhertu (trastuzumab deruxtecan), had been presented at this year’s meeting of the American Society of Clinical Oncology and had been published in the “New England Journal of Medicine”. Enhertu is a specifically engineered HER-2-directed antibody drug conjugate which has…
Dr Coffelt and his team at the Beatson Institute for Cancer Research in Glasgow in another project funded by Secondary1st’s fundraisers and donors are working to understand why existing immunotherapies are less effective in treating breast cancer than other cancer types. They recently published a report on a significant discovery that breast cancer immunotherapy could…
At the University of Bradford in one of the projects funded by the wonderful donors and fundraisers of Secondary1st Professor Pors and his PhD student Enrica are continuing their work to improve duocarmycins, a very effective but highly toxic chemotherapy, so that they can be used to treat breast cancer. In the second year of…
Staff and students from Francis Holland School Regent’s Park put on fancy dress and took part in a sponsored walk around Regent’s Park to raise money for Secondary1st. The weather was ideal to enjoy an autumn afternoon in the open air and the event raised just over £22,000 thanks to the generosity of everyone who…
In recently published draft guidance NICE has approved the routine use of another drug combination for some people with secondary breast cancer. Palbociclib, also known as Ibrance, is a targeted drug made by Pfizer and is now recommended in combination with fulvestrant for the treatment of hormone receptor positive HER2 negative secondary breast cancer when…
Ruth and Stu are preparing to fly to Nepal where they will take part in a 22-day expedition to the summit of Imja Tse, the Nepalese name of Island Peak. Imja Tse is 6200 metres high and is in the Sagarmatha National Park on the Himalayas of eastern Nepal. Island Peak received its English name…
Paul will be running the London Marathon on 2nd October to raise money for Secondary1st in memory of his sister-in-law Poppy. He has been training hard through the summer heat and completed an 18-mile run during the Bank Holiday weekend. He is planning 3 more long runs before Marathon Day.
Catherine did it and more! She walked the length of Hadrian’s Wall and then walked on for another seventeen miles to raise money for Secondary1st. She crossed the country from Wallsend near Newcastle to Bowness-on-Solway near Carlisle keeping any prevailing winds at her back to help her along her journey.
Catherine has spent weeks and weeks preparing for August 2nd when she will set off to walk the 100km length of Hadrian’s Wall east to west across the north of England from Wallsend to Bowness-on-Solway. She hopes to mark the 1900th anniversary of the Wall by completing her walk in eight days.
Final draft guidance from NICE now recommends that two drugs to treat two different types of secondary or metastatic breast cancer be made available through the Cancer Drugs Fund. Piqray or alpelisib is a kinase inhibitor made by Novartis Pharmaceuticals UK. It is to be used with fulvestrant, the hormonal therapy, to treat hormone receptor…
On 2nd August Catherine will set off from Wallsend, Newcastle-Upon-Tyne, to walk the length of Hadrian’s Wall to Bowness-on-Solway in Cumbria. She hopes to complete the 100km distance from coast to coast across Northern England in eight days to raise money for Secondary1st. The construction of Hadrian’s Wall began in 122 A.D. to guard the…
Results of a trial of Enhertu (trastuzumab deruxtecan) were presented at the 2022 meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine. Enhertu is a specifically engineered HER2-directed antibody drug conjugate which looks for breast cancer cells, binds to the HER2 protein on their surface and then…